^
    8ms
    PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Radboud University Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    PORT-3
    over1year
    PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
    P1, N=15, Recruiting, Radboud University Medical Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Immunomodulating
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
    |
    CD20 positive
    |
    PORT-3
    over2years
    PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
    P1, N=15, Recruiting, Radboud University Medical Center | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Immunomodulating
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
    |
    CD20 positive
    |
    PORT-3
    3years
    PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
    P1, N=15, Recruiting, Radboud University Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • Immunomodulating
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
    |
    CD20 positive
    |
    PORT-3
    almost5years
    PRECIOUS-01: Dose Escalation Study of Immunomodulatory Nanoparticles (clinicaltrials.gov)
    P1, N=15, Recruiting, Radboud University
    Clinical • New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • FOXP3 (Forkhead Box P3)
    |
    CD20 positive
    |
    PORT-3